Tumor resistance to antimetabolites
- PMID: 9559310
- DOI: 10.1016/s0306-3623(97)00383-2
Tumor resistance to antimetabolites
Abstract
1. The inherent or acquired resistance of certain tumors to cytotoxic drug therapy is a major clinical problem. 2. Resistance to the chemotherapeutic antimetabolites (e.g., methotrexate, 5-fluorouracil, tomudex and gemcitabine) is no exception. 3. Mechanisms of resistance include mutations, amplification of target genes, altered drug transport, differences in nucleoside and nucleobase salvage pathways, DNA damage-response pathways and cell cycle control pathways.
Similar articles
-
Gemcitabine--status of preclinical studies and perspectives for future clinical applications of this novel nucleoside analog. Symposium proceedings. Amsterdam, The Netherlands, March 15, 1994.Semin Oncol. 1995 Aug;22(4 Suppl 11):1-82. Semin Oncol. 1995. PMID: 7481838 No abstract available.
-
Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.Cancer Lett. 2012 Jul 28;320(2):138-49. doi: 10.1016/j.canlet.2012.03.007. Epub 2012 Mar 13. Cancer Lett. 2012. PMID: 22425961 Free PMC article. Review.
-
Drug resistance in colon cancer.Semin Oncol. 1999 Dec;26(6):606-11. Semin Oncol. 1999. PMID: 10606253 Review.
-
Clinical study of combined use of tomudex (raltitrexed) and xeloda (capecitabine) as first-line treatment for patients with metastasizing colorectal cancer.Bull Exp Biol Med. 2008 Feb;145(2):249-51. doi: 10.1007/s10517-008-0062-1. Bull Exp Biol Med. 2008. PMID: 19023981
-
Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage.Br J Cancer. 1997;75(7):935-45. doi: 10.1038/bjc.1997.164. Br J Cancer. 1997. PMID: 9083327 Free PMC article. Review.
Cited by
-
Chemotherapy agents: a primer for the interventional radiologist.Semin Intervent Radiol. 2010 Dec;27(4):384-90. doi: 10.1055/s-0030-1267852. Semin Intervent Radiol. 2010. PMID: 22550380 Free PMC article.
-
Spatial Analysis of Nucleotide Metabolism: From CRISPR Knockout Cancer Cells to MALDI Imaging of Tumors.Methods Mol Biol. 2023;2675:297-308. doi: 10.1007/978-1-0716-3247-5_22. Methods Mol Biol. 2023. PMID: 37258772
-
From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates.Invest New Drugs. 2006 Jan;24(1):37-77. doi: 10.1007/s10637-005-4541-1. Invest New Drugs. 2006. PMID: 16380836 Review. No abstract available.
-
Optimized peptide based inhibitors targeting the dihydrofolate reductase pathway in cancer.Sci Rep. 2018 Feb 16;8(1):3190. doi: 10.1038/s41598-018-21435-5. Sci Rep. 2018. PMID: 29453377 Free PMC article.
-
Novel antifolate drugs.Curr Oncol Rep. 2003 Mar;5(2):114-25. doi: 10.1007/s11912-003-0098-3. Curr Oncol Rep. 2003. PMID: 12583828 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources